The Law Offices of Frank R. Cruz Files Securities Fraud Lawsuit Against Mesoblast Limited (MESO)

The Law Offices of Frank R. Cruz announces that it has filed a class action lawsuit in the United States District Court for the Southern District of New York, captioned Kristal v. Mesoblast Limited, et al., (Case No. 1:20-cv-08430), on behalf of persons and entities that purchased or otherwise acquired Mesoblast Limited (“Mesoblast” or the “Company”) (NASDAQ: MESO) securities between April 16, 2019 and October 1, 2020, inclusive (the “Class Period”). Plaintiff pursues under Sections 10(b) and 20(a) of the Securities Exchange Act of 1934 (the “Exchange Act”)

If you are a shareholder who suffered a loss, click here to participate.

Mesoblast develops allogeneic cellular medicines using its proprietary mesenchymal lineage cell therapy platform. Its lead product candidate, RYONCIL (remestemcel-L), is an investigational therapy comprising mesenchymal stem cells derived from bone marrow. In February 2018, the Company announced that remestemcel-L met its primary endpoint in a Phase 3 trial

Read More

The Law Offices of Frank R. Cruz Continues Its Investigation of Mesoblast Limited (MESO) on Behalf of Investors

The Law Offices of Frank R. Cruz continues its investigation of Mesoblast Limited (“Mesoblast” or the “Company”) (NASDAQ: MESO) on behalf of investors concerning the Company’s possible violations of federal securities laws.

If you are a shareholder who suffered a loss, click here to participate.

On October 1, 2020, the Company disclosed that it had received a Complete Response Letter (“CRL”) from the U.S. Food and Drug Administration (“FDA”) regarding its marketing application for remestemcel-L for treatment of SR-aGVHD in pediatric patients. According to the CRL, the FDA recommended that Mesoblast “conduct at least one additional randomized, controlled study in adults and/or children to provide further evidence of the effectiveness of remestemcel-L for SR-aGVHD.” The CRL also “identified a need for further scientific rationale to demonstrate the relationship of potency measurements to the product’s biologic activity.”

On this news, Mesoblast’s stock fell $6.53, or 35%, to close at $12.03 per

Read More

The Law Offices of Frank R. Cruz Announces Investigation of Mesoblast Limited (MESO) on Behalf of Investors

The Law Offices of Frank R. Cruz announces an investigation of Mesoblast Limited (“Mesoblast” or the “Company”) (NASDAQ: MESO) on behalf of investors concerning the Company’s possible violations of federal securities laws.

If you are a shareholder who suffered a loss, click here to participate.

On October 1, 2020, the Company disclosed that it had received a Complete Response Letter (“CRL”) from the U.S. Food and Drug Administration (“FDA”) regarding its marketing application for remestemcel-L for treatment of SR-aGVHD in pediatric patients. According to the CRL, the FDA recommended that Mesoblast “conduct at least one additional randomized, controlled study in adults and/or children to provide further evidence of the effectiveness of remestemcel-L for SR-aGVHD.” The CRL also “identified a need for further scientific rationale to demonstrate the relationship of potency measurements to the product’s biologic activity.”

On this news, Mesoblast’s stock fell $6.53, or 35%, to close at $12.03 per

Read More